Skip to content
Search

Latest Stories

RPS calls for national strategy to prevent medicines shortages, greater authority for pharmacists

RPS report on medication shortages
Capsule and empty blister pack (gettyimages)

‘Community pharmacists must be allowed to make minor changes to prescriptions during medicines shortages’

A new report from the Royal Pharmaceutical Society (RPS) has called on the government to create a national strategy to manage medicine shortages and to change legislation to empower community pharmacists to amend prescriptions when medicines are in short supply.

Currently, patients are required to return to their GP to get their prescriptions amended, leading to delayed access to medication, increased bureaucracy, and additional strain on an already overburdened system.


The RPS report, backed by charities and patient groups, proposes allowing pharmacists to make minor amendments, such as adjusting the quantity, strength, or form of prescribed medicines to ensure timely access for patients.

Additionally, the report highlighted key factors causing medicine shortages, including manufacturing and supply chain issues, exacerbated by cost pressures and consolidation of manufacturing outlets.

This along with unplanned spikes in demand, such as shifts in prescribing practice or increased diagnosis of some conditions, have created “a perfect storm of unstable supply”

James Davies, RPS Director for England and co-author of the report, emphasised the need for taking a new approach to medicine shortages.

He explained: “A properly resourced UK-wide medicines shortages strategy that helps prevent and manage shortages would greatly improve the resilience of the supply chain. This would relieve stress and anxiety for patients and free up time for pharmacists to focus on patient care rather than constantly chasing down supplies.

“Community pharmacists must be allowed to make minor changes to prescriptions during shortages,” he said, describing the current system as “outdated.”

“The Secretary of State for Health should give pharmacists the authority to act in the best interests of their patients, rather than remain subject to ‘empty shelf syndrome’,” he added.

Collaborative action needed

Bruce Warner, chair of the advisory group for the report, stressed the importance of improving collaboration across the supply chain and early reporting of shortages by manufacturers.

“Prompt notice of a supply problem allows time to act, find solutions and produce clear guidance, meaning health professionals are fully informed and patients are saved from delays and confusion that can cause distress and harm to health,” he stated.

Sharon Brennan, director of policy and external affairs at National Voices, a coalition of 200 health and social care charities in England, highlighted the challenges facing patients due to medicines shortages.

“Our members report that patients are rationing their medicines to make their supplies last, that deteriorations in health have led to job losses or dropping out of education, and that patients are buying falsified medicines from the internet.”

Brennan underscored that the situation is especially bad for those who are facing health inequalities.

“We urge the Department of Health and Social Care to recognise the serious and worsening impact medication shortages are having on patients, and to commit the same level of urgency to improving the situation as it has to other NHS access-to-care issues such as diagnosis and waiting lists,” she added.

The report also recommends:

  • Improving reporting by manufacturers and imposing fines on those consistently failing to report.
  • Building supply chain resilience by strengthening NHS procurement contracts to ensure manufacturers can meet supply demands and respond to shortages quickly.
  • Boosting data connectivity by using better demand forecasting and sharing information across the supply chain to prevent stock issues before they happen.
  • Enhancing systems for life critical medicines by improving collaboration across the health service to coordinate access to specific medicines.

A daily challenge for pharmacy teams

Janet Morrison, CEO of Community Pharmacy England (CPE), noted that the RPS study closely aligns with their own 2024 Medicines Supply Report, which also highlighted the frustration and inconvenience caused by increasing medicine shortages for pharmacy teams and their patients.

“Patients with a wide range of clinical and therapeutic needs are being impacted now more than ever before, and problems with sourcing their medications have become a daily challenge for pharmacy teams,” she said.

She underlined CPE’s contribution to the report's findings and expressed full support for many of its recommendations.

However, she stressed the urgent need for further action to protect patients and community pharmacies from ongoing supply chain disruptions.

Call for uplift in retained margin 

Malcolm Harrison, chief executive of the Company Chemists’ Association (CCA), has also raised concerns over the rising issue of medicine shortages, stressing the urgent need for “action to improve the resilience of the supply chain.”

He pointed out that since 2014, the volume of medicines has increased by 14% and value by 20%.

To tackle the problem, Harrison suggested, “Both retained margin and drug tariff reimbursement must be uplifted to stop avoidable medicine shortages, to ensure patients can access vital medicines.”

CCA welcomed the findings of the RPS report, which clearly highlight “the frustration felt by patients and pharmacy teams on the frontline.”

Drug shortages add pressure to GPs, pharmacists   

Commenting on the release of the RPS report, Professor Kamila Hawthorne, chair of the Royal College of GPs, acknowledged that medicine supply constraints are a frequent source of concern for patients, and frustration for GPs and pharmacists.

She said: “GPs are already under enormous pressure and any medication shortages, even if they are only temporary, make the situation worse.

“There may be many reasons for medication shortages – it's essential that when they occur, the reason for them is identified and addressed as soon as possible.”

She believes that the recommendations outlined in this report, including a national strategy to prevent and manage medication shortages when they occur, would go a long way to making the situation easier for everyone involved.

Nick Kaye, chair of the National Pharmacy Association (NPA), also pointed out that medicine shortages put pressure on already overstretched pharmacy teams, forcing them to "spend hours hunting down stock when they could be helping patients."

To fix this frustrating situation for the long term, he urged the health secretary to instigate “an end-to-end review of the medicines supply chain” to ensure it is fit for the future.

NPA has been calling for the appointment of a medicine shortages Tsar, to get a grip within government on this growing and complex crisis.

About the RPS report, Kaye said: "This is a really important piece of work and rightly recognises that pharmacists are highly trained health care practitioners, who should be permitted to use their professional judgment to supply an appropriate alternative medicine in the event of the prescribed version being unavailable.”

Action is needed now

Duncan Rudkin, CEO of the General Pharmaceutical Council (GPhC), commented that they fully agree with the RPS report’s conclusion that further action is needed now.

He stated: “Although the GPhC has no direct role in medicines supply, we are determined to play our part in the next steps wherever possible, including in educating pharmacy teams about medicines shortages, and supporting them through our standards and guidance when they are facing challenging situations.”

Roz Gittins, chief pharmacy officer at the GPhC, added that they would welcome changes to legislation to enable community pharmacists to make minor changes to prescriptions when medicines are unavailable, as they do in hospital.

The council also strongly supports the call in the report to improve the sharing of data and information throughout the system, to enable national and local teams to more proactively manage supply and demand.

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
​The next generation of BD Rowa Smart launched

The latest BD Rowa™ Smart introduces a more intuitive user interface.

Photo credit: BD Rowa

BD Rowa unveils next-generation smart dispensing robot with sustainable design

Leading medical technology company BD Rowa has announced the launch of the next generation of its smart dispensing robot, offering enhanced convenience with a sustainable design.

Currently in its final development phase, the latest BD Rowa™ Smart introduces a more intuitive user interface designed to streamline operations and enhance the user experience.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less